Moleculin Biotech, Inc.
MBRX is overvalued
NASDAQ · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$2.10
MARKET PRICE
$1.80
FAIR PRICE
$0.30
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy MBRX?
No one has priced MBRX yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when MBRX's fair price changes
Push notifications when MBRX's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels, but below-average fundamental quality and volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$1.44
Fair price × 0.80
DISTANCE
31.4%
Price to entry level
At the current price of $2.10, MBRX trades 31.4% above the conservative entry level of $1.44. This entry level represents a 20% margin of safety below the calculated fair price of $1.80 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate MBRX's fair price
Moleculin Biotech, Inc.'s fair price of $1.80 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $2.10, MBRX trades 14.3% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting MBRX's risk profile.
RELATIVE · 30%
Comparing MBRX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for MBRX, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate MBRX's fair value with your own inputs.
MBRX DCF Calculator
Pre-filled with MBRX's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter MBRX's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of MBRX's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare MBRX against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for MBRX.
Explore on BuliosFAQ
What is the fair price of MBRX?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Moleculin Biotech, Inc. is $1.80. At the current market price of $2.10, MBRX trades 14.3% above its calculated fair value.
Is MBRX overvalued or undervalued?+
Moleculin Biotech, Inc. is currently overvalued based on our valuation model. The stock trades at $2.10, which is 14.3% above the fair price of $1.80.
What is the margin of safety for MBRX?+
With a 20% margin of safety applied to the fair price of $1.80, the conservative entry level for MBRX is $1.44. At the current market price of $2.10, the stock trades 31.4% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is MBRX's fair price updated?+
We update fair price calculations for MBRX daily after market close. The current fair price of $1.80 incorporates the latest market data and sector multiples.
What factors affect MBRX's fair price calculation?+
MBRX's fair price of $1.80 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 589.5%.
Is MBRX a good buy right now?+
At $2.10, MBRX trades 14.3% above our fair value estimate of $1.80. The stock is currently overvalued. ROE stands at 589.5% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does MBRX pay dividends?+
MBRX does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.